Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment
Journal of Internal Medicine · 2024
DOI: 10.1111/joim.13772 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, 2024. Verfasst von Magnus Ingelman-Sundberg und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Section of Pharmacogenetics, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Precision Medicine, Cardiovascular Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Research Council, Medical Research Council.
Abstract (Originalsprache)
Pharmacogenomics is the examination of how genetic variation influences drug metabolism and response, in terms of both efficacy and safety. In cardiovascular disease, patient‐specific diplotypes determine phenotypes, thereby influencing the efficacy and safety of drug treatments, including statins, antiarrhythmics, anticoagulants and antiplatelets. Notably, polymorphisms in key genes, such as CYP2C9, CYP2C19, VKORC1 and SLCO1B1 , significantly impact the outcomes of treatment with clopidogrel, warfarin and simvastatin. Furthermore, the CYP2C19 polymorphism influences the pharmacokinetics and safety of the novel hypertrophic cardiomyopathy inhibitor, mavacamten. In this review, we critically assess the clinical application of pharmacogenomics in cardiovascular disease and delineate present and future utilization of pharmacogenomics. This includes insights into identifying missing heritability, the integration of whole genome sequencing and the application of polygenic risk scores to enhance the precision of personalized drug therapy. Our discussion encompasses health economic analyses that underscore the cost benefits associated with pre‐emptive genotyping for warfarin and clopidogrel treatments, albeit acknowledging the need for further research in this area. In summary, we contend that cardiovascular pharmacogenomic analyses are underpinned by a wealth of evidence, and implementation is already occurring for some of these gene–drug pairs, but as with any area of medicine, we need to continually gather more information to optimize the use of pharmacogenomics in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Section of Pharmacogenetics, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden.
- Wolfson Centre for Personalised Medicine, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
ORCID-Profile: Magnus Ingelman-Sundberg
Förderung
- European Research Council
- Medical Research Council
Zitieren
APA
Ingelman-Sundberg, M., & Pirmohamed, M. (2024). Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. Journal of Internal Medicine. https://doi.org/10.1111/joim.13772
Vancouver
Ingelman-Sundberg M, Pirmohamed M. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. Journal of Internal Medicine. 2024. doi:10.1111/joim.13772
BibTeX
@article{IngelmanSundberg2024,
author = {Ingelman-Sundberg, Magnus and Pirmohamed, Munir},
title = {Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment},
journal = {Journal of Internal Medicine},
year = {2024},
doi = {10.1111/joim.13772}
}
EUVIMED